




The relative strengths and weaknesses of NGM Biopharmaceuticals INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of NGM Biopharmaceuticals INC compared to the market average is the variable Stockholders Equity, increasing the Economic Capital Ratio by 148% points. The greatest weakness of NGM Biopharmaceuticals INC is the variable Research and Development, reducing the Economic Capital Ratio by 46% points.

The company's Economic Capital Ratio, given in the ranking table, is 297%, being 84% points above the market average of 213%.

Input Variable	Value in 1000 USD
Assets, Current	156,444
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	20,081
Liabilities, Non-Current	149
Other Assets	5,391
Other Compr. Net Income	320
Other Expenses	0
Other Liabilities	0
Other Net Income	9,088
Other Revenues	4,417
Property and Equipment	7,033
Research and Development	118,040
Selling, General and Administrative Expense	37,840

Output Variable	Value in 1000 USD
Assets	168,868
Liabilities	20,230
Expenses	155,880
Revenues	4,417
Stockholders Equity	148,638
Net Income	-142,375
Comprehensive Net Income	-142,215
BaseVar	179,402
ECR before LimitedLiability	192%
Economic Capital Ratio	297%